Navigating the complex landscape of legal acquisition for controlled substances, specifically Schedule I drugs, represents a particularly niche area for registered Québécois institutions—typically research facilities—and demands meticulous adherence to strict regulations. This process goes far beyond standard supplier selection, encompassing